News & Analysis as of

Biologics Samsung

Goodwin

Biogen and Samsung BioLogics Close Asset Transfer Deal

Goodwin on

As we previously reported, Biogen has exercised its option to purchase additional shares of Samsung Bioepis, increasing Biogen’s ownership in the Samsung Bioepis joint venture from approximately 5.4% to approximately...more

Goodwin

IPR Updates

Goodwin on

The PTAB remains a busy venue for biologics patents. Here are some IPR updates from the weeks since our last IPR update...more

Patterson Belknap Webb & Tyler LLP

US Biosimilar Pathway Update

Six years after the biosimilar pathway was enacted into law, FDA has approved three biosimilars for marketing in the US. Sandoz’s Zarxio, a biosimilar of Amgen’s Neupogen, was the first biosimilar to be approved. Zarxio, a...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide